Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems

Liver disease represents a growing global health burden. The development of in vitro liver models which allow the study of disease and the prediction of metabolism and drug-induced liver injury in humans remains a challenge. The maintenance of functional primary hepatocytes cultures, the parenchymal cell of the liver, has historically been difficult with dedifferentiation and the consequent loss of hepatic function limiting utility. The desire for longer term functional liver cultures sparked the development of numerous systems, including collagen sandwiches, spheroids, micropatterned co-cultures and liver microphysiological systems. This review will focus on liver microphysiological systems, often referred to as liver-on-a-chip, and broaden to include platforms with interconnected microphysiological systems or multi-organ-chips. The interconnection of microphysiological systems presents the opportunity to explore system level effects, investigate organ cross talk, and address questions which were previously the preserve of animal experimentation. As a field, microphysiological systems have reached a level of maturity suitable for commercialization and consequent evaluation by a wider community of users, in academia and the pharmaceutical industry. Here scientific, operational, and organizational considerations relevant to the wider adoption of microphysiological systems will be discussed. Applications in which microphysiological systems might offer unique scientific insights or enable studies currently feasible only with animal models are described, and challenges which might be addressed to enable wider adoption of the technologies are highlighted. A path forward which envisions the development of microphysiological systems in partnerships between academia, vendors and industry, is proposed. Impact statement Microphysiological systems are in vitro models of human tissues and organs. These systems have advanced rapidly in recent years and are now being commercialized. To achieve wide adoption in the biological and pharmaceutical research communities, microphysiological systems must provide unique insights which translate to humans. This will be achieved by identifying key applications and making microphysiological systems intuitive to use.

[1]  Yvonne Will,et al.  Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  Manjunath Hegde,et al.  In vitro platforms for evaluating liver toxicity , 2014, Experimental biology and medicine.

[3]  Shuichi Takayama,et al.  Quantitative Analysis of Molecular Absorption into PDMS Microfluidic Channels , 2012, Annals of Biomedical Engineering.

[4]  Michael L Shuler,et al.  Design and demonstration of a pumpless 14 compartment microphysiological system , 2016, Biotechnology and bioengineering.

[5]  Melvin E. Andersen,et al.  Organotypic liver culture models: Meeting current challenges in toxicity testing , 2012, Critical reviews in toxicology.

[6]  Martin L Yarmush,et al.  Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans. , 2014, Toxicology and applied pharmacology.

[7]  Andreas Hierlemann,et al.  96-Well Format-Based Microfluidic Platform for Parallel Interconnection of Multiple Multicellular Spheroids , 2015, Journal of laboratory automation.

[8]  M. Ingelman-Sundberg,et al.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease , 2016, Scientific Reports.

[9]  Chitra Kanchagar,et al.  Establishment of a Hepatocyte-Kupffer Cell Coculture Model for Assessment of Proinflammatory Cytokine Effects on Metabolizing Enzymes and Drug Transporters , 2015, Drug Metabolism and Disposition.

[10]  Uwe Marx,et al.  Chip-based human liver-intestine and liver-skin co-cultures--A first step toward systemic repeated dose substance testing in vitro. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  Michael L Shuler,et al.  Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. , 2015, Integrative biology : quantitative biosciences from nano to macro.

[12]  Thierry Lavé,et al.  Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling , 2017, The AAPS Journal.

[13]  Alan Wells,et al.  A microphysiological system model of therapy for liver micrometastases , 2014, Experimental biology and medicine.

[14]  Hongbin Yu,et al.  Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac , 2018, Drug Metabolism and Disposition.

[15]  John P. Wikswo,et al.  Real-Time Cellular Exometabolome Analysis with a Microfluidic-Mass Spectrometry Platform , 2015, PloS one.

[16]  Manjunath Hegde,et al.  Long-term maintenance of a microfluidic 3D human liver sinusoid. , 2016, Biotechnology and bioengineering.

[17]  D. Beebe,et al.  Biological implications of polydimethylsiloxane-based microfluidic cell culture. , 2009, Lab on a chip.

[18]  S. Bhatia,et al.  In vitro zonation and toxicity in a hepatocyte bioreactor. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  P. Ganey,et al.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  L. Griffith,et al.  Modeling Therapeutic Antibody–Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform , 2016, Drug Metabolism and Disposition.

[21]  R. Tompkins,et al.  Oxygen uptake rates in cultured rat hepatocytes. , 1992, Biotechnology and bioengineering.

[22]  Luke P. Lee,et al.  Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications , 2015, Scientific Reports.

[23]  Jeffrey B. Gross,et al.  Timing of New Black Box Warnings and Withdrawals for Prescription Medications , 2003 .

[24]  M. Yarmush,et al.  Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. , 2009, Biochemical pharmacology.

[25]  Z. Cui,et al.  In situ three-dimensional characterization of membrane fouling by protein suspensions using multiphoton microscopy. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[26]  Martin L Yarmush,et al.  A novel low-volume two-chamber microfabricated platform for evaluating drug metabolism and toxicity. , 2015, Technology.

[27]  K. Brouwer,et al.  Species Differences in Hepatobiliary Disposition of Taurocholic Acid in Human and Rat Sandwich-Cultured Hepatocytes: Implications for Drug-Induced Liver Injury , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[28]  L. Griffith,et al.  Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system , 2014, British Journal of Cancer.

[29]  Martin L. Yarmush,et al.  Isolation and co-culture of rat parenchymal and non-parenchymal liver cells to evaluate cellular interactions and response , 2016, Scientific Reports.

[30]  M. Yarmush,et al.  A microfluidic hepatic coculture platform for cell-based drug metabolism studies. , 2010, Biochemical pharmacology.

[31]  Aaron Sin,et al.  Development of a Microscale Cell Culture Analog To Probe Naphthalene Toxicity , 2008, Biotechnology progress.

[32]  L. Samson,et al.  A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. , 2005, Current drug metabolism.

[33]  Nwe Ni Than,et al.  A concise review of non-alcoholic fatty liver disease. , 2015, Atherosclerosis.

[34]  Gordana Vunjak-Novakovic,et al.  HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease , 2013, Stem Cell Research & Therapy.

[35]  D. B. Duignan,et al.  Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites , 2010, Drug Metabolism and Disposition.

[36]  P. Watkins,et al.  Stable isotope resolved metabolomics of primary human hepatocytes reveals a stressed phenotype , 2012, Metabolomics.

[37]  S. Klieber,et al.  Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device , 2015, Xenobiotica; the fate of foreign compounds in biological systems.

[38]  Volker M Lauschke,et al.  Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. , 2016, Chemical research in toxicology.

[39]  William McLamb,et al.  Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs , 2016, Scientific Reports.

[40]  Matthew H. M. Lim,et al.  Perfused multiwell plate for 3D liver tissue engineering. , 2010, Lab on a chip.

[41]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[42]  Andreas Manz,et al.  On-chip three-dimensional cell culture in phaseguides improves hepatocyte functions in vitro. , 2015, Biomicrofluidics.

[43]  Delilah F. G. Hendriks,et al.  Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability , 2016, Scientific Reports.

[44]  Uwe Marx,et al.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. , 2016, ALTEX.

[45]  John P. Wikswo,et al.  Engineering Challenges for Instrumenting and Controlling Integrated Organ-on-Chip Systems , 2013, IEEE Transactions on Biomedical Engineering.

[46]  C. Ryan,et al.  Isolation and long-term culture of human hepatocytes. , 1993, Surgery.

[47]  David J Hughes,et al.  Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease , 2017, World journal of gastroenterology.

[48]  Ludovic Vallier,et al.  Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. , 2010, The Journal of clinical investigation.

[49]  D. Lauffenburger,et al.  Fusing Tissue Engineering and Systems Biology Toward Fulfilling Their Promise , 2008 .

[50]  Yuki Imura,et al.  Micro total bioassay system for ingested substances: assessment of intestinal absorption, hepatic metabolism, and bioactivity. , 2010, Analytical chemistry.

[51]  Daniel C Leslie,et al.  A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.

[52]  Michael Bauer,et al.  A microfluidically perfused three dimensional human liver model. , 2015, Biomaterials.

[53]  E. Roberts,et al.  Extended primary culture of human hepatocytes in a collagen gel sandwich system , 1997, In Vitro Cellular & Developmental Biology - Animal.

[54]  A. Lane,et al.  Stable Isotope-Resolved Metabolomics by NMR. , 2019, Methods in molecular biology.

[55]  D. Kyle,et al.  Microphysical space of a liver sinusoid device enables simplified long-term maintenance of chimeric mouse-expanded human hepatocytes , 2014, Biomedical microdevices.

[56]  A. Kashuba,et al.  Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[57]  Mandy B. Esch,et al.  Modular, pumpless body-on-a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue. , 2016, Lab on a chip.

[58]  Walker Inman,et al.  Liver tissue engineering in the evaluation of drug safety , 2009, Expert opinion on drug metabolism & toxicology.

[59]  M. Maes,et al.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. , 2015, Progress in lipid research.

[60]  J. Kelm,et al.  Multi-cell type human liver microtissues for hepatotoxicity testing , 2012, Archives of Toxicology.

[61]  L. Griffith,et al.  Metabolite Profiling and Pharmacokinetic Evaluation of Hydrocortisone in a Perfused Three-Dimensional Human Liver Bioreactor , 2015, Drug Metabolism and Disposition.

[62]  Stefan Przyborski,et al.  Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. , 2011, Assay and drug development technologies.

[63]  L. Griffith,et al.  Bioreactor technologies to support liver function in vitro. , 2014, Advanced drug delivery reviews.

[64]  Thomas Singer,et al.  A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. , 2013, Toxicology and applied pharmacology.

[65]  M L Shuler,et al.  Combining Cell Culture Analogue Reactor Designs and PBPK Models to Probe Mechanisms of Naphthalene Toxicity , 2000, Biotechnology progress.

[66]  E. Verpoorte,et al.  Comparison of biocompatibility and adsorption properties of different plastics for advanced microfluidic cell and tissue culture models. , 2012, Analytical chemistry.

[67]  P. Ganey,et al.  Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity—Two Villains or One? , 2010, Journal of Pharmacology and Experimental Therapeutics.

[68]  Daniel C Leslie,et al.  Clear castable polyurethane elastomer for fabrication of microfluidic devices. , 2013, Lab on a chip.

[69]  Jan G Hengstler,et al.  Use of a standardised and validated long-term human hepatocyte culture system for repetitive analyses of drugs: repeated administrations of acetaminophen reduces albumin and urea secretion. , 2007, ALTEX.

[70]  Lucas H. Hofmeister,et al.  Scaling and systems biology for integrating multiple organs-on-a-chip. , 2013, Lab on a chip.

[71]  Jan Vanfleteren,et al.  Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction , 2016, Proceedings of the National Academy of Sciences.

[72]  L. Griffith,et al.  Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[73]  K. Jungermann,et al.  Oxygen: Modulator of metabolic zonation and disease of the liver , 2000, Hepatology.

[74]  N. Voelcker,et al.  Recent developments in PDMS surface modification for microfluidic devices , 2010, Electrophoresis.

[75]  A. Hierlemann,et al.  3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis. , 2015, Journal of biotechnology.